Medicines (Rx) 
Oral Painkiller “Oraphine® 60mg Soft Capsule” Awarded by the Ministry of Health and Welfare and the Ministry of Economic Affairs
2020 . 12 . 15
PhytoHealth Corporation (4108) has announced that its innovative painkiller, "Oraphine® 60mg Soft Capsule", has been awarded the 2020 Silver Medal in the category of Drugs by the Ministry of Health and Welfare and the Ministry of Economic Affairs. This oral dosage form of painkiller, designed to treat moderate to severe pain, features the active ingredient "Nalbuphine", which offers the benefits of low addiction potential and a reduced risk of respiratory depression, thereby enhancing medication safety and convenience.
The Pharmaceutical Science and Technology Research and Development Award, co-sponsored by the Ministry of Health and Welfare and the Ministry of Economic Affairs, is the only interministerial research and development award in the country. It recognizes excellence in three categories: Drugs, Medical Equipment, and Manufacturing Technology. The announcement of the final results by Hsueh Jui-Yuan, Undersecretary of the Ministry of Health and Welfare, underscores PhytoHealth's innovative research and development achievements as a source of national pride.
Despite the absence of gold medals in the Drugs category this year, PhytoHealth's Oraphine® 60mg Soft Capsule secured the silver medal. The corporation has a long-standing commitment to the research and development of oral painkillers and has successfully transformed injectable painkillers for the treatment of moderate to severe pain into oral dosage forms. This development overcomes the issue of reduced drug efficacy due to liver metabolism and has successfully obtained marketing authorization from the Ministry of Health and Welfare this year.
Angel Lee, Vice Chairman of PhytoHealth, highlighted that the active ingredient "Nalbuphine" used in Oraphine® 60mg Soft Capsule not only has low addiction potential and a reduced risk of respiratory depression but also has fewer usage restrictions. This enhances medication safety and, coupled with the fact that the oral dosage forms and active ingredients are Non-Controlled Drugs, further improves medication convenience.
The new painkiller Oraphine® 60mg Soft Capsule fully complies with the US FDA's "Risk Evaluation and Mitigation Strategy" standards. PhytoHealth is currently in active negotiations with the U.S., Japan, and mainland China to secure authorization, aiming for royalty or licensing fees and royalties from new drug sales. The corporation is targeting the global painkiller market, which has a potential value of up to 40 billion US dollars.
The Pharmaceutical Science and Technology Research and Development Award, co-sponsored by the Ministry of Health and Welfare and the Ministry of Economic Affairs, is the only interministerial research and development award in the country. It recognizes excellence in three categories: Drugs, Medical Equipment, and Manufacturing Technology. The announcement of the final results by Hsueh Jui-Yuan, Undersecretary of the Ministry of Health and Welfare, underscores PhytoHealth's innovative research and development achievements as a source of national pride.
Despite the absence of gold medals in the Drugs category this year, PhytoHealth's Oraphine® 60mg Soft Capsule secured the silver medal. The corporation has a long-standing commitment to the research and development of oral painkillers and has successfully transformed injectable painkillers for the treatment of moderate to severe pain into oral dosage forms. This development overcomes the issue of reduced drug efficacy due to liver metabolism and has successfully obtained marketing authorization from the Ministry of Health and Welfare this year.
Angel Lee, Vice Chairman of PhytoHealth, highlighted that the active ingredient "Nalbuphine" used in Oraphine® 60mg Soft Capsule not only has low addiction potential and a reduced risk of respiratory depression but also has fewer usage restrictions. This enhances medication safety and, coupled with the fact that the oral dosage forms and active ingredients are Non-Controlled Drugs, further improves medication convenience.
The new painkiller Oraphine® 60mg Soft Capsule fully complies with the US FDA's "Risk Evaluation and Mitigation Strategy" standards. PhytoHealth is currently in active negotiations with the U.S., Japan, and mainland China to secure authorization, aiming for royalty or licensing fees and royalties from new drug sales. The corporation is targeting the global painkiller market, which has a potential value of up to 40 billion US dollars.
The original article：《經濟日報》懷特痛寶口服止痛藥 獲衛福部、經濟部頒藥品最高榮譽